Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorotriphenylmethane SCHEMBL461 | 0.84 | TSHR (0.65) | TSHRCYP19A1CYP1A2KCNN4ALDH1A1 | |
| Chlorotriphenylmethane SCHEMBL16781670 | 0.84 | TSHR (0.65) | TSHRCYP19A1CYP1A2KCNN4ALDH1A1 | |
| SCHEMBL15087403 | 0.82 | KCNN4 (0.48) | TSHRCYP19A1CYP1A2KCNN4CYP3A4 | |
| Chlorotriphenylmethane SCHEMBL7567317 | 0.81 | TSHR (0.61) | TSHRCYP19A1CYP1A2KCNN4ALDH1A1 | |
| Chlorotriphenylmethane SCHEMBL11237663 | 0.81 | TSHR (0.61) | TSHRCYP19A1CYP1A2KCNN4ALDH1A1 | |
| Chlorotriphenylmethane SCHEMBL29446246 | 0.81 | TSHR (0.61) | TSHRCYP19A1CYP1A2KCNN4ALDH1A1 | |
| Chlorotriphenylmethane SCHEMBL113884 | 0.81 | TSHR (0.61) | TSHRCYP19A1CYP1A2KCNN4ALDH1A1 | |
| Chlorotriphenylmethane SCHEMBL7246540 | 0.81 | TSHR (0.61) | TSHRCYP19A1CYP1A2KCNN4ALDH1A1 | |
| SCHEMBL12305490 | 0.79 | TSHR (0.52) | TSHRCYP19A1CYP1A2KCNN4ALDH1A1 | |
| SCHEMBL1361594 | 0.79 | TSHR (0.52) | TSHRCYP19A1CYP1A2KCNN4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183966-B2 | Solid phase peptide synthesis via side chain attachment | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2019-01-22 | — | — | US | disclosed |
| US-20160362445-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2016-12-15 | — | — | US | disclosed |
| US-20160362445-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2016-12-15 | — | — | US | disclosed |
| US-9388212-B2 | Solid phase peptide synthesis via side chain attachment | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2016-07-12 | — | — | US | disclosed |
| US-9388212-B2 | Solid phase peptide synthesis via side chain attachment | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2016-07-12 | — | — | US | disclosed |
| US-20140235789-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2014-08-21 | — | — | US | disclosed |
| US-20140235789-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2014-08-21 | — | — | US | disclosed |
| WO-2013098802-A2 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362445-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | HDGF, VIP, HDGFL3 | TSHR 1749/4885CYP19A1 4004/4885CYP1A2 4212/4885 |
| US-20140235789-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | HDGF, VIP, HDGFL3 | TSHR 1749/4885CYP19A1 4004/4885CYP1A2 4212/4885 |
| US-10183966-B2 | Solid phase peptide synthesis via side chain attachment | HDGF, VIP, HDGFL3 | TSHR 1749/4885CYP19A1 4004/4885CYP1A2 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.